Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 2/20 | 0.35 |
| ▸ | CES1 | P23141 | 2/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | LCLAT1 | Q6UWP7 | 1/20 | 0.34 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16955165 | 0.84 | KMT2A (0.39) | KRASKMT2ANPC1SMN1; SMN2RAB9A | |
| SCHEMBL1260103 | 0.81 | KMT2A (0.36) | KRASKMT2ANPC1SMN1; SMN2RAB9A | |
| SCHEMBL1261333 | 0.81 | KMT2A (0.50) | KRASKMT2ANPC1SMN1; SMN2RAB9A | |
| SCHEMBL16954603 | 0.80 | KRAS (0.36) | KRASKMT2ANPC1SMN1; SMN2RAB9A | |
| SCHEMBL1261656 | 0.80 | KMT2A (0.35) | KRASKMT2ANPC1SMN1; SMN2RAB9A | |
| SCHEMBL23980121 | 0.80 | ALDH1A1 (0.46) | KMT2ANPC1SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL5279376 | 0.79 | KRAS (0.38) | KRASKMT2ANPC1SMN1; SMN2RAB9A | |
| SCHEMBL16951697 | 0.79 | KMT2A (0.38) | KRASKMT2ANPC1SMN1; SMN2RAB9A | |
| SCHEMBL5279382 | 0.79 | KRAS (0.38) | KRASKMT2ANPC1SMN1; SMN2RAB9A | |
| SCHEMBL10433490 | 0.78 | CA1 (0.47) | KMT2ANPC1ALDH1A1MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017140669-A1 | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS | SANOFI (FR) | 2017-08-24 | — | — | WO | disclosed |
| EP-1994005-B9 | TETRAHYDRONAPHTHALINE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | Bayer Pharma AG (DE) | 2012-01-11 | — | — | EP | disclosed |
| EP-1994005-B1 | TETRAHYDRONAPHTHALINE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AG (DE) | 2011-07-20 | — | — | EP | disclosed |
| US-7880042-B2 | antiinflammatory agents; (5 alpha ,6 alpha ,8 beta )-2-fluoro-8-methyl-5-[(2-methylquinoline-5-yl)amino]-6-(trifluoromethyl)-5,6,7,8-tetrahydronaphthalene-1,6-diol; side effect reduction | BAYER SCHERING PHARMA AG (DE) | 2011-02-01 | — | — | US | disclosed |
| US-20100298311-A1 | TETRAHYDRONAPHTHALENE DERIVATES, PROCESS FOR PREPARING THEM AND THEIR USE AS ANTIINFLAMMATORY AGENTS | BERGER MARKUS | 2010-11-25 | — | — | US | disclosed |
| EP-1994005-A1 | TETRAHYDRONAPHTHALINE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-11-26 | — | — | EP | disclosed |
| US-20070225290-A1 | Tetrahydronaphthalene derivates, processes for preparing them and their use as antiinflammatory agents | BAYER SCHERING PHARMA AG (DE) | 2007-09-27 | — | — | US | disclosed |
| WO-2007104582-A1 | TETRAHYDRONAPHTHALINE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225290-A1 | Tetrahydronaphthalene derivates, processes for preparing them and their use as antiinflammatory agents | TNF, IL1B, DHPS | KRAS 3248/4885KMT2A 4701/4885NPC1 1582/4885 |
| US-20100298311-A1 | TETRAHYDRONAPHTHALENE DERIVATES, PROCESS FOR PREPARING THEM AND THEIR USE AS ANTIINFLAMMATORY AGENTS | TNF, IL1B, DHPS | KRAS 3442/4885KMT2A 4694/4885NPC1 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.